ALPHAFOLD
Google opens up latest AI models to 200 European researchers
Google has unveiled a groundbreaking initiative to provide 200 European researchers access to its cutting-edge AI models as part of the Resource for AI Science in Europe scheme. This access includes advanced tools like AlphaFold 3 and WeatherNext, aiming to boost scientific research capabilities. The move is designed to foster innovation in Europe's research landscape, coinciding with rising demands for stricter regulations on AI technologies.
There could be a pretty big global shock, says Nobel laureate & economist Michael Spence
Michael Spence highlights the economic growth of India and China, noting India's potential growth trajectory. He emphasizes India's advancements in digital infrastructure, particularly in digital financial services like UPI. Spence discusses the significance of AI in economic development and its anticipated impact over the next decade. He warns of potential economic shocks due to rising debt levels and high market valuations.
COVID-19 had a scientific head start; the next pandemic virus may be a stranger. NVIDIA and Google DeepMind are using AI to map 2,800 viruses before the next outbreak
An international collaboration has developed a dataset of predicted protein structures from more than 2,800 viruses. This data is accessible through the AlphaFold Database, aiding in pandemic preparedness. Researchers can accelerate their investigations of new viruses using this information for potential treatments. The dataset provides insights into protein interactions, making it a valuable resource for global scientists.
At 13, a Texas student uses AI to study one of the deadliest brain cancers: says, ‘It started with curiosity’; aims to combine AI with biomedicine
Thirteen-year-old Myreen Ahsan is at the forefront of innovation, delving into the realms of advanced AI tools to aid brain cancer research. Focusing on glioblastoma, she utilizes RNA-based aptamers to selectively target malignant cells. Through self-learning and persistence, Myreen has successfully presented her findings at a university symposium, aspiring to spark further medical breakthroughs and inspire her peers in scientific inquiry.
Nobel Prize winner John Jumper quits Google DeepMind after nearly a decade; set to join Anthropic
Nobel laureate John Jumper, a key figure behind the groundbreaking AlphaFold AI, is departing Google DeepMind after nearly nine years. He announced his move to rival AI firm Anthropic on X. Jumper's departure underscores the intense competition for top AI talent as startups like Anthropic vie with tech giants for leading researchers.
Google’s Isomorphic Labs to raise over $2 billion in new funding
Alphabet's AI drug discovery firm, Isomorphic Labs, is reportedly close to securing over $2 billion in new funding, led by Thrive Capital. This significant investment aims to bolster its drug design engine and fuel global expansion, underscoring Alphabet's strategy of commercializing its advanced AI ventures.
Man with no medical degree creates cancer vaccine using ChatGPT for his sick pet. Open AI CEO Sam Altman reacts: ‘This should be easy ….’
An Australian businessman, Paul Conyngham, used AI tools like ChatGPT and AlphaFold to develop a personalized mRNA cancer treatment for his dog, Rosie. This remarkable endeavor, which involved collaboration with scientists and veterinarians, has sparked discussions about AI's potential in personalized healthcare, though experts urge caution due to limited evidence of efficacy and the need for rigorous validation.
Silicon Valley-based FaiBLE Media launches with focus on AI storytelling in India
Silicon Valley startup FaiBLE Media Inc. has launched with a mission to decode the science of storytelling using AI. Co-founded by Sharad Devarajan and Dr. Mark Sagar, the company aims to develop new media experiences, including 'Quantum Stories' that offer non-linear narrative paths. FaiBLE seeks to identify scientific patterns behind emotional resonance in stories, inspired by scientific breakthroughs like AlphaFold.
AI driven Innovations in targeted drug delivery: The emergence of needless syringes.
Scientists are developing AI-designed molecular syringes. These syringes use modified bacterial proteins. They target specific cells for drug delivery. DeepMind's AlphaFold helps in precise targeting. Tests show promising results in vitro and in mice. This innovation could revolutionize gene therapy and cancer treatment. It enables controlled drug release and reduces side effects. Researchers envision programmable delivery devices for various therapies.
Google’s missed opportunity: Sundar Pichai on the Netflix deal that nearly happened
The Google CEO said there were many “small regrets” over the years, particularly around missed acquisitions, but clarified the Netflix deal that didn’t happen couldn’t be termed a regret.
Gen Beta, watch out: AI poised to take a big leap in 2025
While such predictions remain speculative, developments in AI over the next few years are easier to foresee. So, what transformative changes can we expect from AI in the year 2025 and beyond?
Google’s triumph on the Nobel stage resolves a 50-year-old mystery
AlphaFold 2, an AI model developed through Google’s DeepMind initiative, cracked the code for predicting complex protein structures from amino acid sequences. It resulted in the accurate prediction of nearly 200 million known proteins. AlphaFold has been used by over two million researchers globally, in areas such as antibiotic resistance and creating enzymes capable of breaking down plastics.
2024 Nobel Prize in Chemistry: Who are David Baker, Demis Hassabis and John Jumper?
2024 Nobel Prize in Chemistry Winner: The 2024 Nobel Prize in Chemistry honored David Baker for computational protein design and Demis Hassabis alongside John M. Jumper for predicting protein structures using AI. Their groundbreaking work on proteins promises significant advancements in pharmaceuticals, vaccines, and understanding biological mechanisms.
Will AI one day win a Nobel Prize?
Some scientists are already hard at work seeking to create an AI colleague worthy of a Nobel, with this year's laureates to be announced between October 7 and 14. And in fact, there are around 100 "robot scientists" already, according to Ross King, a professor of machine intelligence at Chalmers University in Sweden.
India well positioned as shift to AI happens: Google CEO Sundar Pichai
Pichai, who is also the chief executive of Alphabet, Google's parent company, was talking a day after announcing several of Google's innovations in his keynote address at Google I/O connect, the company's annual developer conference. "AI tools for a lot of our products... India is number one country in terms of user base. To be able to serve them we're committed to bringing the same AI tools," Pichai said.
Google DeepMind unveils next generation of drug discovery AI model
With the latest incarnation of AlphaFold, researchers at DeepMind and sister company Isomorphic Labs - both overseen by cofounder Demis Hassabis - have mapped the behaviour for all of life's molecules, including human DNA.
Mark Zuckerberg's philanthropy project plans AI system for life sciences research
The Chan Zuckerberg Initiative, created by Zuckerberg and his wife Priscilla Chan, will use the computing system to run openly available AI models, the philanthropy venture said on Tuesday.
With AI, let's not move fast and break things
One of these Pandora's boxes is labeled "artificial intelligence," and it is exemplified by the likes of ChatGPT, Bard and AlphaFold, which testify to humanity's ability for the first time to manufacture something in a godlike way that approaches general intelligence, far exceeding the brainpower with which we evolved naturally.
A database of 200 million-plus protein shapes is hypercharging biomedical research
So far, scientists have been using X-ray crystallography to find out the shape of proteins. This is expensive and time-consuming. Of course, AlphaFold’s forecasts would need to be confirmed the old-fashioned way. But the time taken to confirm a hypothesis, already given to you, is far less than what is spent on forming alternate hypotheses.
Load More
